Naoki Niikura
Overview
Explore the profile of Naoki Niikura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
2106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamilton E, Loibl S, Bachelot T, Gnant M, Niikura N, Park Y, et al.
Future Oncol
. 2025 Feb;
21(7):795-806.
PMID: 40017004
Novel selective estrogen receptor degraders (SERDs) are a promising therapeutic option under investigation for patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The efficacy of...
2.
McArthur H, Tolaney S, Dent R, Schmid P, Asselah J, Liu Q, et al.
Ther Adv Med Oncol
. 2025 Feb;
17:17588359251316176.
PMID: 39917260
Background: Despite treatment advances for patients with early-stage triple-negative breast cancer (TNBC) and hormone receptor (HR)-low/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, treatments that improve clinical outcomes while...
3.
Nagahashi M, Kumamaru H, Kinukawa N, Iwamoto T, Kawashima M, Kinoshita T, et al.
Breast Cancer
. 2025 Feb;
32(2):217-226.
PMID: 39910023
This is an annual report by the Japanese Breast Cancer Society, which provides statistics on the clinical data on breast cancer in Japan, extracted from the National Clinical Database-Breast Cancer...
4.
Yamamoto Y, Iwata H, Saji S, Takahashi M, Yoshinami T, Ueno T, et al.
J Clin Oncol
. 2025 Jan;
JCO2401673.
PMID: 39854662
In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with...
5.
Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, et al.
Nat Med
. 2024 Dec;
30(12):3780.
PMID: 39653780
No abstract available.
6.
Nakayama T, Niikura N, Yamanaka T, Yamamoto M, Matsuura K, Inoue K, et al.
Breast Cancer
. 2024 Sep;
31(6):1184.
PMID: 39302559
No abstract available.
7.
Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, et al.
Nat Med
. 2024 Sep;
30(12):3717-3727.
PMID: 39271844
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2-positive (HER2) advanced/metastatic breast cancer (mBC) and stable or active...
8.
Nakayama T, Niikura N, Yamanaka T, Yamamoto M, Matsuura K, Inoue K, et al.
Breast Cancer
. 2024 Aug;
31(6):1167-1175.
PMID: 39133378
We provide updated results (median follow-up duration: 20.4 months) of a retrospective study on the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+)...
9.
Kazama T, Nagafuji Y, Niikura N, Okamura T, Van Cauteren M, Obara M, et al.
Magn Reson Med Sci
. 2024 Jul;
PMID: 39069474
Purpose: High b-value acquisition and diffusion-weighted imaging with background suppression (DWIBS) are desirable in high-specificity breast cancer diagnosis on non-contrast-enhanced magnetic resonance imaging; however, this inherently results in a lower...
10.
Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, et al.
Breast Cancer Res Treat
. 2024 Jun;
208(2):253-262.
PMID: 38922548
Purpose: This study aimed to determine whether the 21-Gene Breast Recurrence Score® assay from primary breast tissue predicts the prognosis of patients with hormone receptor-positive and human epidermal growth factor...